AU2007255041A1 - Benzoxazole and benzothiazole derivatives as 5-hydroxytrytamine-6 ligands - Google Patents

Benzoxazole and benzothiazole derivatives as 5-hydroxytrytamine-6 ligands Download PDF

Info

Publication number
AU2007255041A1
AU2007255041A1 AU2007255041A AU2007255041A AU2007255041A1 AU 2007255041 A1 AU2007255041 A1 AU 2007255041A1 AU 2007255041 A AU2007255041 A AU 2007255041A AU 2007255041 A AU2007255041 A AU 2007255041A AU 2007255041 A1 AU2007255041 A1 AU 2007255041A1
Authority
AU
Australia
Prior art keywords
benzoxazole
piperazin
naphthylsulfonyl
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2007255041A
Other languages
English (en)
Inventor
Hassan Mahmoud Elokdah
Kevin Liu
Albert Jean Robichaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of AU2007255041A1 publication Critical patent/AU2007255041A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2007255041A 2006-06-01 2007-05-25 Benzoxazole and benzothiazole derivatives as 5-hydroxytrytamine-6 ligands Abandoned AU2007255041A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80999606P 2006-06-01 2006-06-01
US60/809,996 2006-06-01
PCT/US2007/012569 WO2007142904A2 (en) 2006-06-01 2007-05-25 Benzoxazole and benzothiazole derivatives as 5-hydroxytrytamine-6 ligands

Publications (1)

Publication Number Publication Date
AU2007255041A1 true AU2007255041A1 (en) 2007-12-13

Family

ID=38668755

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007255041A Abandoned AU2007255041A1 (en) 2006-06-01 2007-05-25 Benzoxazole and benzothiazole derivatives as 5-hydroxytrytamine-6 ligands

Country Status (17)

Country Link
US (1) US7501421B2 (enExample)
EP (1) EP2024348A2 (enExample)
JP (1) JP2009538909A (enExample)
KR (1) KR20090023641A (enExample)
CN (1) CN101490022A (enExample)
AR (1) AR061147A1 (enExample)
AU (1) AU2007255041A1 (enExample)
BR (1) BRPI0712444A2 (enExample)
CA (1) CA2659701A1 (enExample)
CR (1) CR10474A (enExample)
EC (1) ECSP088930A (enExample)
IL (1) IL195590A0 (enExample)
MX (1) MX2008015328A (enExample)
NO (1) NO20085045L (enExample)
PE (1) PE20080707A1 (enExample)
TW (1) TW200804310A (enExample)
WO (1) WO2007142904A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174125A1 (en) * 2009-04-02 2011-10-28 Merck Serono Sa Dihydroorotate dehydrogenase inhibitors
KR101250606B1 (ko) * 2011-01-24 2013-04-03 이화여자대학교 산학협력단 5-ｈｔ６ 수용체 억제 작용을 갖는 신규한 벤조티아졸 및 벤즈이소티아졸유도체, 이의 제조 방법 및 이를 포함하는 약학적 조성물
US9890142B2 (en) 2013-07-10 2018-02-13 Meiji Seika Pharma Co., Ltd. PDE4 inhibitor
AU2015286049B2 (en) 2014-07-08 2018-03-01 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic derivatives and pharmaceutical applications thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7582635B2 (en) 2002-12-24 2009-09-01 Purdue Pharma, L.P. Therapeutic agents useful for treating pain
GB0422263D0 (en) * 2004-10-07 2004-11-10 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
CR10474A (es) 2009-01-07
CN101490022A (zh) 2009-07-22
US7501421B2 (en) 2009-03-10
AR061147A1 (es) 2008-08-06
TW200804310A (en) 2008-01-16
JP2009538909A (ja) 2009-11-12
ECSP088930A (es) 2009-01-30
NO20085045L (no) 2008-12-12
BRPI0712444A2 (pt) 2012-06-05
PE20080707A1 (es) 2008-05-22
WO2007142904A2 (en) 2007-12-13
CA2659701A1 (en) 2007-12-13
KR20090023641A (ko) 2009-03-05
WO2007142904A3 (en) 2008-02-07
US20070281945A1 (en) 2007-12-06
EP2024348A2 (en) 2009-02-18
MX2008015328A (es) 2008-12-12
IL195590A0 (en) 2009-09-01

Similar Documents

Publication Publication Date Title
US20070281922A1 (en) 1-Sulfonylindazolylamine and - amide derivatives as 5-hydroxytryptamine-6 ligands
US7259165B2 (en) Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands
JP2005532349A (ja) ５−ヒドロキシトリプタミン−６リガンドとしての１−（アミノアルキル）−３−スルホニルアザインドール
MX2011004996A (es) 1-(arilsulfonil)-4-(piperazin-1-il)-1h-benzimidazoles como ligandos de 5-hidroxitriptamina-6.
AU2004259739A1 (en) Sulfonyldihydro- benzimidazolone compounds as 5-hydroxytryptamine-6 ligands
US7414051B2 (en) Substituted-dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands
US7501421B2 (en) Benzoxazole and benzothiazole derivatives as 5-hydroxytryptamine-6 ligands
CA2543627A1 (en) Sulfonyltetrahydro-3h-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
US20070244179A1 (en) Dihydro[1,4]dioxino[2,3-e]indazole derivatives as 5-hydroxytryptamine-6 ligands
US7482461B2 (en) Sulfonyl-3-heterocyclylindazole derivatives as 5-hydroxytryptamine-6 ligands
US7429582B2 (en) Dihydro[1,4]oxazino[2,3,4-hi]indazole derivatives as 5-hydroxytryptamine-6 ligands and use thereof in the treatment of attention deficit disorders
WO2008144299A1 (en) 5- (aminoazacyclyl) -3-sulfonyl-lh- indazoles as 5-hydroxytryptamine- 6 ligands for the treatment of cns disorders

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period